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To determine whether individual autophosphoryla- 
tion sites in  the  epidermal  growth  factor  (EGF)  receptor 
define specific interaction sites for  the in vivo associa- 
tion of signal  transduction  proteins  that  contain src ho- 
mology  2  (SH2)  domains, the capacity of wild-type  and 
mutant EGF receptors to associate with  several SH2 do- 
main-containing  proteins has been  assayed.  Mutants in- 
cluded  receptors  with single autophosphorylation site 
mutations at each of five autophosphorylation sites and 
receptors  in  which  multiple  autophosphorylation sites 
were  removed by point  mutation  or deletion of carboxyl- 
terminal residues. Receptor  association, as measured by 
coimmunoprecipitation, has been  determined  for  phos- 
pholipase C-yl, the ras GTPase-activating  protein,  the 
p85 subunit of phosphatidylinositol  3-kinase,  and the src 
homology  and  collagen  protein.  In  contrast to data  ob- 
tained  with single autophosphorylation site mutants of 
other  receptor  tyrosine kinases, none of the EGF recep- 
tor single site mutants  was  dramatically  impaired in its 
capacity to associate with any of these SH2-containing 
proteins. However, association was completely abro- 
gated  when  all five autophosphorylation sites were  mu- 
tated  or  removed by deletion. These results indicate  that 
individual  autophosphorylation sites in the EGF recep- 
tor  are  not  stringently  required  for the recognition  and 
association of different  SH2-containing  substrates. 
Thus, EGF receptor  autophosphorylation sites seem to 
be flexible andor compensatory in their capacity to 
mediate association with these four  SH2-containing 
substrates. 
A key feature  to  the  mechanism of signal  transduction by 
receptor tyrosine  kinase  is  the recognition of receptor  motifs 
containing phosphotyrosyl residues by intracellular proteins 
that  contain src homology 2  (SH2)’  motifs (1, 2). This recogni- 
tion event,  the specificity of which is considered to depend on 
sequences surrounding  the phosphotyrosyl residue  as well as 
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sequences within each SH2  domain,  leads to  high  affinity as- 
sociation of activated receptors and SH2-containing molecules. 
While some SH2-containing molecules are used as phosphory- 
lation  substrates by receptor  tyrosine kinases,  others  are not 
phosphorylated, but function as  adaptors to mediate complex 
formation  between  receptors and  other  cellular proteins. 
Current evidence indicates  that  many of these SH2-contain- 
ing  proteins  mediate  the  signal  transduction process initiated 
by growth  factors.  SH2-containing signal  proteins  that  interact 
with  the  activated  EGF receptor  include  enzymes such  as phos- 
pholipase (2-71, ras GTPase-activating  protein (rasGAP) (3,4), 
and  the syp phosphotyrosine phosphatase ( 5 , 6 )  as well as non- 
enzymatic  adaptor molecules such as the p85 subunit of phos- 
phatidylinositol 3-kinase  (7, 81, the src homology and collagen 
protein  (SHC) (91, GRB-2 (lo), and Nck (11-13). Many of these 
SH2-containing proteins also associate with other activated 
receptor tyrosine  kinases (1-12). 
The basis of the interaction between SH2-containing pro- 
teins  and receptor  tyrosine kinases  has been  most  extensively 
studied  with  autophosphorylation  site  mutants of the  platelet- 
derived growth factor (PDGF) receptor, which contains eight 
known autophosphorylation  sites.  The  results of these  studies 
demonstrate  that  mutagenesis of one particular autophospho- 
rylation site selectively and significantly abrogates  the asso- 
ciation of one (14-19) and,  in one instance, two (20) SH2-con- 
taining molecules with  the  activated receptor. Thus,  individual 
autophosphorylation  sites  in  the  PDGF receptor are  stringently 
required for particular  SH2-containing molecules to  associate 
with  and,  in some cases, be phosphorylated by the  PDGF re- 
ceptors.  Analyses of autophosphorylation site  mutants  in 
colony stimulating factor 1 (21), fibroblast growth factor (22, 
23), and nerve growth factor (NGF) (24, 25) receptors have 
provided similar  results. 
When  autophosphorylation site  mutants of the  EGF receptor 
were  analyzed for their capacity to form complexes with ras- 
GAP, no single autophosphorylation  site  mutant  was  dramati- 
cally deficient in  this  interaction,  suggesting a lack of stringent 
selectivity  (26). However, 10-fold less rasGAP was  able  to form 
an association complex with  the  activated wild-type EGF  re- 
ceptor  compared with  the  activated  PDGF receptor. This  might 
indicate a low affinity interaction between rasGAP and the 
EGF receptor, perhaps  due  to  the  absence of a high affinity 
binding  site. 
In  this study, we have  analyzed  the capacity of three  addi- 
tional SH2-containing substrates  to form complexes with wild- 
type  and  autophosphorylation  site  mutants of the  EGF recep- 
tor. The results indicate that the EGF receptor model for 
recognition of at least four SH2-containing  substrates differs 
significantly  from data  acquired  with  other r ceptors and imply 
novel facets to  the recognition mechanism between  phosphoty- 
rosyl-containing  sequences and  SH2-containing  substrates. 
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EXPERIMENTAL PROCEDURES 
Materials-EGF was isolated from mouse submaxillary gland ac- 
cording to the method of Savage and Cohen (27). 12sII-Labeled goat 
anti-mouse IgG and 12sII-labeled protein  A  were  obtained from ICN Ra- 
diochemicals.  Protein  A-Sepharose CL-4B was from Sigma.  Protein G- 
Sepharose 4B, polyclonal antibodies to  phosphotyrosine, and mono- 
clonal  antibodies  to  the  intracellular  domain of the  human  EGF 
receptor  were  from Zymed Laboratories, Inc. Monoclonal antibodies  to 
the  human  EGF receptor  extracellular  domain  and polyclonal antibod- 
ies to rasGAP and the p85 subunit of phosphatidylinositol 3-kinase 
were  obtained from Upstate Biotechnology, Inc. Monoclonal antibodies 
to  phospholipase C-yl  (28)  were  kindly provided by Dr. Sue Goo Rhee 
(National  Institutes of Health),  and polyclonal antibodies  were  as de- 
scribed  previously  (29). Polyclonal antibodies to  SHC  were  purchased 
from  Transduction  Laboratories. 
EGFReceptor  Mutants  and Cell Culture-Human  EGF  receptor  mu- 
tants were  obtained  using  site-directed  mutagenesis to  substitute  tyro- 
sine  residues  with  phenylalanine or to  delete coding sequence for dif- 
ferent carboxyl terminus  fragments,  previously  described  (26). Mouse 
NIH3T3 cells, which contain -3000 endogenous EGF receptorsicell, 
were  used for human  receptor  transfections. As determined by '2sII-EGF 
binding  assay  (29),  the  mutant  receptors  were  expressed a t  high (3-5 x 
lo5) or low (0.7-1.6 x IO5) levels of receptors  per cell. For  comparative 
controls,  either of two cell lines,  wt-1  expressing  high  (4 x lo5) or wt-2 
expressing low (1 x IO5) levels of wild-type receptor  per cell, was  used. 
Cells  were  maintained in Dulbecco's modified Eagle's medium  contain- 
ing  10%  newborn calf serum  and  gentamicin  (50  pgiml). 
Growth  Factor  neatment-Transfected  NIH3T3  cells  were  grown to  
-90% confluence in Dulbecco's modified Eagle's medium containing 
10% newborn calf serum  and  subsequently  incubated  overnight  in Dul- 
becco's modified Eagle's  medium  containing 0.5%' newborn calf serum. 
The cells were  then  incubated  without or with  EGF i 100  ngiml) for 1 h 
a t  4 "C in Dulbecco's modified Eagle's medium  supplemented  with 20 
mM Hepes, pH 7.4, and 0.1% bovine serum albumin. The capacity of 
EGF receptors to autophosphorylate, to phosphorylate cellular sub- 
strates,  and  to associate  with  SH2-containing  substrates  is  not  altered 
when cells are  incubated  at  4 "C. Control experiments demonstrated 
that maximal  EGF-induced  receptor-SH2-containing  substrate  associa- 
tion  is  achieved  under  these  conditions. 
Immunoprecipitation-After  growth  factor  treatment,  cultures  were 
washed  with ice-cold Ca2+/Mg2+-free  phosphate-buffered  saline  and  solu- 
bilized in lysis  buffer (1% Triton X-100, 10% glycerol, 50 mM Hepes, pH 
7.2, 100 mM NaC1, 1 mM Na,VO,, 1 mM phenylmethylsulfonyl  fluoride, 
10 pgiml leupeptin, 10 pgiml aprotinin,  and  544 VM iodoacetamide) for 
15 min a t  4 "C. The  lysates  were  then  clarified by centrifugation  (12,000 
x g ,  10 min)  at 4 "C. Receptor  precipitation  was  performed  using  mouse 
monoclonal antibodies  to  the  extracellular  domain of the  human  EGF 
receptor  (Clone LA1, Upstate Biotechnology, Inc.)  and  protein  G-Sepha- 
rose 4B beads.  Phospholipase C-yl, rusGAP, the p85  subunit of phos- 
phatidylinositol  3-kinase,  and  SHC  were  precipitated  with specific rab- 
bit antisera and protein A-Sepharose CL-4B beads. Controls showed 
that  the  antisera were not limiting. Immunocomplexes were washed 
four  times  with  buffer  containing  20 mM Hepes, pH 7.2,  100 mM NaCl, 
0.1% Triton X-100, 10% glycerol, and 1 mM Na,VO,. Samples were 
boiled in Laemmli  buffer  (30)  prior  to  separation of proteins on 7.5% 
SDS-polyacrylamide  gels  and  transfer to  nitrocellulose  paper, 
Western BZot Analysis-The amount of receptor-associated phospho- 
lipase  C-yl,  rasGAP,  p85  subunit of phosphatidylinositol  3-kinase,  or 
SHC  was  detected by Western blot analysis of receptor  immunoprecipi- 
tates  using monoclonal antibodies to  phospholipase C-yl or polyclonal 
antibodies  to rasGAP, p85, or SHC.  The  amount of EGF  receptor  im- 
munoprecipitated was determined by immunoblotting using mono- 
clonal antibodies to the intracellular domain of the human receptor 
(Clone 2025, Zymed Laboratories, Inc.). Since the receptor mutant 
Dc214 lacks the intracellular antigenic sequence of the Clone 2025 
antibody,  immunoblots of this  receptor  were  performed  with  a mono- 
clonal  antibody  to the  extracellular  domain of the  human  EGF receptor 
(Clone LA22, Upstate Biotechnology, Inc.).  The  amount of phosphory- 
lated  EGF  receptor  in  the  different  SH2-containing  substrate  immuno- 
precipitations  was  detected by blotting  with  phosphotyrosine  antibody. 
Membranes  were blocked for 1 h a t  room temperature  in 5% nonfat 
dry milWTBST (0.05% Tween 20,150 mM NaC1, and 50 mM Tris, pH  7.4) 
and  incubated  with  the  indicated  primary  antibody for 2 h. After wash- 
ing  with TBST, blots  were  incubated  for 1 h  with '"I-protein A or with 
'2sII-labeled goat  anti-mouse IgG to  detect  primary  rabbit polyclonal or 
mouse monoclonal antibodies, respectively. Blots were then washed 
TA~LE I 
Quantitation of SH2-containing  substrate-actiuated 
EGF receptor complexes 
NIH3T3 cells expressing  transfected  human wild-type EGF  receptor 
were serum-starved overnight, incubated without or with EGF (100 
ngiml) for 1 h a t  4 "C, and  then solubilized in lysis buffer. The EGF 
receptor, phospholipase C-yl, rasGAP, p85, or SHC was immunopre- 
as  indicated under "Experimental Procedures." SH2-containing sub- 
cipitated,  electrophoresed,  and  transferred to  nitrocellulose  membranes 
strates  that coprecipitated with the EGF receptor or phosphorylated 
receptor that coprecipitated  with  each  SH2-containing  substrate  was 
analyzed by immunoblotting. To determine  the  amount of each copre- 
cipitating  protein  relative to  the  total  cellular  content of that  protein, 
increasing  amounts of whole cell lysate were electrophoresed, trans- 
ferred  to  nitrocellulose  membranes,  and  analyzed by Western  blotting 
to  construct  a  standard  curve for each  protein. 
SH2 substrate 
Total cell substrate 
associated 
Total phosphorylated 
with receptor with SH2 substrate 
receptor associated 
% 57 
PLC-y1" 0.8 0.5 





" PLC-yl,  phospholipase  C-yl; ND, not detectable. 
with TBST. Reactive  bands  were  quantitated  using  a  PhosphorImager 
(Molecular  Dynamics,  Inc.). 
RESULTS AND DISCUSSION 
Before analyzing  the influence of autophosphorylation site 
mutations on the formation of association complexes between 
the  EGF receptor and  the SH2-containing substrates phospho- 
lipase C-yl, rasGAP, p85, and SHC, experiments were per- 
formed to quantitate these associations in cells expressing 
wild-type receptors. The coimmunoprecipitation data in Table I 
indicate the  amount of each  SH2-containing  protein present  in 
immunoprecipitation complexes with  activated EGF receptors 
relative to the total cellular level of that protein. A similar 
quantitation  is  made for the  amount of phosphorylated EGF 
receptor. Under  these conditions, at  least 50%' of the  total cel- 
lular pool of EGF receptors is phosphorylated. Clearly, these 
complexes represent very small  fractions of the  total cellular 
pool of each molecule. The  data suggest that among the four 
SH2-containing  proteins tested, SHC may form the  largest  and 
rusGAP the  smallest  amount of association complex with the 
EGF receptor. 
Certain coimmunoprecipitation experiments with the PDGF 
and NGF receptors have concluded that multiple substrates 
may be associated  simultaneously  with one receptor molecule, 
creating a multimeric complex (25,311. We attempted  to detect 
such complexes with the  EGF receptor. However, when cells 
treated with EGF  are immunoprecipitated  with antisera to one 
SH2-containing  protein, we detect only that protein  associated 
with the  EGF receptor. Attempts  to detect the presence of a 
second SH2-containing protein in these immunoprecipitates 
have been unsuccessful.  These experiments  have included im- 
munoprecipitation of phospholipase C-yl, rasGAP, or SHC 
from EGF-treated cells and  subsequent Western  blotting  with 
antibodies to  the two heterologous substrates. Since the  data in 
Table I indicate  that only very small amounts of receptor (<3%) 
are ever  associated with one SH2-containing  protein, it  seems 
unlikely that  EGF receptor complexes with  multiple SH2-con- 
taining  substrates  are formed. 
Analysis of Single Autophosphorylation Sites-To determine 
whether an individual autophosphorylation site in the EGF 
receptor is  essential for the association of each of four SH2- 
containing proteins, coprecipitation experiments were per- 
formed with cells expressing wild-type or mutant  human  EGF 
receptors having a single Tyr + Phe  substitution at each of the 
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FIG. 1. Association of SH2-containing  substrates  with EGF re- 
ceptor  single  autophosphorylation site mutants. Cells  expressing 
EGF receptor single autophosphorylation site mutants were treated 
without or  with EGF (100 ng/ml) for 1 h at  4 "C and  then  solubilized in 
lysis buffer. The EGF receptor was immunoprecipitated as indicated 
under "Experimental  Procedures,"  electrophoresed, and transferred to 
nitrocellulose  membranes.  Immunoprecipitated  EGF  receptor (EGFR) 
and receptor-associated phospholipase C-yl (PLC-y1 , rasGAP, p85, 
and SHC were analyzed by immunoblotting. 1173F,  1148F,  1086F, 
1068F. and 992F are EGF  receptor mutants with  phenylalanine sub- 
stituted for  tyrosine. A transfected cell line expressing high numbers of 
wild-type  EGF receptors (wt-1) was matched with cell lines expressing 
similar high  numbers of mutant receptors  (Y992F,  Y1148F. and 
Y1068F). Cell lines expressing low numbers of the receptor mutants 
Y1086F  and  Y1173F were matched  with a cell line  expressing a similar 
low number of wild-type  EGF  receptors (wt-2). Autoradiograms of the 
latter group of cell lines  were  exposed  for a longer period of time, so the 
data appear  equivalent o the results from cells expressing a high num- 
ber of receptors. 
five known autophosphorylation sites (tyrosines 1173, 1148, 
1086, 1068, and 992).  After  growth  factor treatment,  EGF re- 
ceptors were immunoprecipitated and analyzed for the pres- 
ence of phospholipase C-yl, rusGAP, p85, and SHC by Western 
blotting. Since  receptor  immunoprecipitations  were performed 
with an antibody specific for human  (but not  mouse) EGF  re- 
ceptors, the low number of endogenous EGF receptors present 
in  these cells does not contribute  to  the coprecipitations. 
The data in Fig. 1 show Western blots for phospholipase 
C-yl, rusGAP, p85, and SHC in receptor  immunoprecipitates. 
Also, the blots show the  amount of EGF receptor in each  im- 
munoprecipitate. The  primary  data from these Western  blots 
are  quantitated  and normalized for the  amount of immunopre- 
cipitated  receptors in Table 11. These  results  demonstrate  that 
no single autophosphorylation site  mutant  was  dramatically 
impaired  in  its capacity to associate  with any of the four  SH2- 
containing  proteins analyzed. The only statistically significant 
decreases were 35 and 37% for phospholipase C-yl  and p85 
association with mutant Y1173F, respectively. No other mu- 
tant-substrate pair exhibited a statistically significant de- 
crease  in association capacity. Tyrosine 1173 has been reported 
to be the major EGF receptor  autophosphorylation site in  intact 
cells (32). 
These  results  contrast  with  the very substantial reductions 
(>80% or nondetectable  levels) observed with  single  autophos- 
phorylation site  mutants of the PDGF  receptor and phospho- 
lipase  C-yl  (14, 151, rusGAP, p85 (16-181, syp (191, Nck (20), 
and  src (33). SHC association  with the PDGF  receptor has not 
been reported. Also, a single mutation of the fibroblast  growth 
factor  receptor  significantly disrupts phospholipase C-yl asso- 
ciation (22,23),  and single mutations of the NGF  receptor pro- 
duce substantial decreases in association  capacity  with phos- 
TABLE I1 
Quantitation of association of SH2-containing  substrates  with EGF 
receptor single autophosphorylation  site  mutants 
Cells expressing  the indicated EGF  receptors  (described in the legend 
to Fig. 1) were assayed for phospholipase C-yl, rasGAP,  p85,  and SHC 
association as indicated for Fig. 1. The  amount of each  SH2-containing 
substrate associated  with immunoprecipitated receptors  was  corrected 
for the amount of immunoprecipitated  receptor.  Data are expressed  as 
percent of SH2-containing substrate associated  with the wild-type re- 
ceptor and correspond  to the mean f S.E. of at least  three  independent 
experiments.  Since  the  amounts of receptor  and/or  receptor-associated 
SH2-containing substrate are very low, the error inherent in these 
measurements is expectedly high and is reflected in the  values obtained 
from different  experiments. 
EGF receptor 
Receptor-associated substrate (9 of wild-type) 
PLC-yl" rasGAPh ~ 8 5  SHC 
Wild-type 100 100 100 100 
Y1173F 6 5 t  10' 83 t32  63 t2d  82 t23  
Y1148F 11Ot 14 622  19 125227 181.~31 
Y1086F 11Ot26 89237 1892 10 173246 
Y1068F 81 2 10 7 2 t  15 82226  127t32 
Y992F 1 1 4 t 2 6  76227 118k23 1482 16 
Phospholipase C-yl. 
* From Ref. 26. 
' p  < 0.5 (Student's t test). 
p < 0.001 (Student's t test). 
pholipase C-yl (24) and p85 and SHC (25). For the EGF 
receptor, different  methods of analysis  have suggested the as- 
sociation of the SH2-containing proteins phospholipase C-yl 
(34)  and GRB-2 (35) with Tyr-992 and Tyr-1068, respectively. 
The phospholipase C-yl  data  are derived from an  in vitro meas- 
urement of the protection by EGF receptor-associated phospho- 
lipase C-yl SH2 domains of different receptor autophospho- 
rylation sites  against dephosphorylation by exogenous 
phosphatase. Our data do not  necessarily  contradict this result. 
While receptor-associated phospholipase C-yl may be prefer- 
entially associated  with one or two autophosphorylation sites 
in  the wild-type receptor, our  data show that in the  intact cell, 
the association-recognition basis in  the EGF receptor is suffi- 
ciently flexible that  other  sites  are  able  to compensate when 
Tyr-992 is  not available. 
These  results  indicate  that individual  autophosphorylation 
sites  in  the EGF  receptor are not stringently required for the 
association of a t  least  these four  SH2-containing  signaling  sub- 
strates.  These  results  are  in  agreement with  prior studies of 
these individual  autophosphorylation site  mutants, which have 
shown no decrease in EGF-dependent  growth  (36) and  trans- 
formation (37)* capacities relative  to  the wild-type EGF recep- 
tor. 
Influence of Multiple Autophosphorylution Site Mutu- 
tions-To determine how the loss of multiple autophosphoryla- 
tion sites  might affect the capacity of the activated  EGF recep- 
tor  to  interact with phospholipase C-yl, rusGAP, p85, or SHC, 
the coimmunoprecipitation experiments shown in Fig. 2 and 
quantitated  in Table I11 were performed. In  the  F5  and Dc214 
mutants,  all five autophosphorylation sites  have been removed 
by site-directed mutagenesis  to phenylalanine or by truncation 
at residue 972, respectively. The data show that neither of 
these receptor mutants forms association complexes with any 
of the four  SH2-containing  proteins examined. Therefore, au- 
tophosphorylation sites  are  required for the observed associa- 
tions. 
The  other two mutants examined in Table I11 are a double 
mutant  (F2) affecting Tyr-1173 and Tyr-1148 and a triple mu- 
tant  (F3)  altering Tyr-1173, Tyr-1148, and Tyr-1068. For phos- 
pholipase C-yl,  these  data  together with the  results on mutant 
Y1173F (Table 11) show a progressive decrease  in  association 
* L. Beguinot,  unpublished results. 
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FIG. 2. Association of SH2-containing substrates with EGF re- 
ceptor mutants lacking multiple autophosphorylation sites.  
Cells  expressing  the  indicated  wild-type  and  mutant  EGF (EGFR) re- 
ceptors  were  tested for phospholipase  C-yl (PLC-yI ), rasGAP, p85, and 
SHC association as described for Fig. 1. The  F2  receptor  mutant  has 
phenylalanine  substitutions a t  Tyr-1173 and Tyr-1148; the  F3  receptor 
mutant has phenylalanine substitutions a t  Tyr-1173, Tyr-1148, and 
Tyr-1068; and  the F5 receptor mutant  has  phenylalanine  substitutions 
a t  Tyr-1173, Tyr-1148, Qr-1086, Tyr-1068, and Tyr-992. The Dc214 
receptor mutant  lacks  the  last 214 carboxyl-terminal  amino acid resi- 
dues, which include all five known autophosphorylation  sites. As in Fig. 
1, cell lines  expressing  high or low numbers of mutant  EGF  receptors 
were  matched  with cell lines  expressing  high  (wt-1) or low (wt-2)  num- 
bers of EGF  receptors.  Autoradiogram  exposure  time for blots  derived 
from cells expressing low numbers of EGF receptors was longer to 
produce  autoradiogram  intensities  equivalent  to  those f r the blots from 
cells expressing  high  numbers of receptors. 
TABLE I11 
Quantitation of association  ofSH2-containing  suhstrates  with EGF 
receptors having mutations at multiple  autophosphorylation  sites 
Cells  expressing  the  indicated  EGF  receptors  (described  in  the legend 
to  Fig.  2)  were  tested for phospholipase C-yl, rasGAP, p85, and  SHC 
association as  indicated for Fig. 1. The  amount of each  SH2-containing 
substrate associated  with  immunoprecipitated  receptors  was  corrected 
for the  amount of immunoprecipitated receptor. Data  are expressed as  
percent of SH2-containing substrate associated  with the wild-type  re- 
ceptor  and  correspond  to  the  mean f S.E. of at  least  three  independent 
experiments. 
EGF receptor 
Receptor-associated substrate ('X of wild-type) 
PLC-VI" rasGAPh ~ 8 5  SHC 
Wild-type 100 100 100 100 
F2 51f 12' 35+.9" 86+. 12'' 2 5 f 4 d  
F3 
F5 
20+  11" 18 f 12" 49 f 17" 17+. 9" 
ND 6 9" ND ND 
Dc214 ND ND ND ND 
PLC-11, phospholipase  C-yl; ND, not  detectable. ' From Ref. 26. 
'p c 0.001 (Student's t test). 
" p  c 0.001 (Student's t test). 
' p  c 0.05 (Student's t test). 
capacity with the loss of multiple autophosphorylation sites: 
Tyr-1173 (35%), Tyr-1173 and Tyr-1148 (49%), and  5r-1173, 
Tyr-1148, and Tyr-1068 (806). These  data  agree  with  the pre- 
viously described effect of these mutations on EGF-induced 
phosphoinositide hydrolysis and intracellular Ca2+ increase 
(38). 
A significant  autophosphorylation  site for  phospholipase 
C-yl  appears  to be Tyr-1173, which has a sequence motif simi- 
lar  to  that of the  unique phospholipase C-yl association sites  in 
the  NGF  (24)  and fibroblast growth factor  (22, 23) receptors, 
but different from that of the stringent phospholipase C-yl 
association site  in  the  PDGF receptor  (14, 15). The  EGF recep- 
tor Tyr-992 sequence motif is  similar  to  that of the PDGF  re- 
ceptor  phospholipase C-yl association site. However, phospho- 
lipase  C-yl association  with the  EGF receptor is unaffected by 
mutation a t  Tyr-992. Our single  autophosphorylation site mu- 
tant  data (Table 11) and  the in vitro results of others  (39)  using 
phosphotyrosine-containing peptides  to each  autophosphoryla- 
tion site do not suggest a unique phospholipase C-yl-binding 
site  in  the  EGF receptor. Rather,  the phospholipase C-yl asso- 
ciation data  in Table I11 suggest a cumulative  requirement of 
autophosphorylation  sites for maximal  phospholipase C-yl as- 
sociation with the  EGF receptor. 
The  data with rusGAF' from Tables I1 and I11 seem similar  to 
the phospholipase C-yl  data  in  that a progressive reduction in 
EGF receptor  association  capacity is recorded with the loss of 
Tyr-1173 (27'7r), Tyr-1173 and Tyr-1148 (65%) and Tyr-1173, 
Tyr-1148, and Tyr-1068 (82%)). 
In contrast to SHC, rusGAP, and phospholipase C-yl, the 
association of p85  with the  EGF receptor is significantly less 
affected in the  F2  and F3 mutants (Table 111). Interestingly, no 
EGF receptor  autophosphorylation site  has  the consensus motif 
Y(M/V)XM, which is stringently required for p85 association 
with PDGF  (16,  18), colony stimulating factor 1 (21),  and NGF 
(25) receptors. Recently, a novel motif ( Y V X V )  for p85 associa- 
tion with the hepatocyte  growth  factor  receptor has been iden- 
tified (40).  The sequence a t  Tyr-1173 of the EGF receptor is 
YLRV, and  it may sufficiently resemble the p85 motif in the 
hepatocyte  growth  factor  receptor to explain the small  decrease 
observed with the single mutation at  this  site. Nevertheless, 
the association data with the  F2  and  F3  mutants indicate that 
other autophosphorylation sites  are able  to mediate p85 asso- 
ciation effectively in  the absence of Tyr-1173. 
Of the four  SH2-containing  proteins assayed, only the asso- 
ciation of SHC  is  dramatically reduced (75%)  in  the  F2  mutant 
(Table III),  suggesting  that  the coordinate loss of Tyr-1173 and 
Tyr-1148 cannot be compensated by the  other  three autophos- 
phorylation sites. Since single mutations a t  Tyr-1173 or Tyr- 
1148 did not significantly  reduce  SHC  association, it  seems  that 
either Tyr-1173 or Tyr-1148 can mediate significant levels of 
SHC association  with the  EGF receptor. A  SHC-binding site  has 
been identified only in  the NGF receptor (25)  and  has a se- 
quence motif of NPQYFSD. This sequence has some similarity 
to  the Tyr-1148 autophosphorylation site (NPDYQQD) of the 
EGF receptor, but  not to the Tyr-1173 site. Alternatively, SHC 
may be the most sensitive of the four  SH2-containing  proteins 
tested  to  the loss of two  autophosphorylation sites because it 
has a  single SH2 domain. The  other  three  proteins  tested have 
two  different SH2  domains, which may provide additional flex- 
ibility in phosphotyrosine-SH2 interactions. 
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